William F. Glass, M.D.

William Glass II, MD
Professor of Pathology

EDUCATION:

Medical School: University of Texas, 1985
Residency: University of Texas
Surgical Pathology Fellowship: University of Texas

CLINICAL:

Pathology: Anatomic

REFERENCES:

1: Lin JS, Mamlouk O, Selamet U, Tchakarov A, Glass WF, Sheth RA, Layman RM, Dadu R, Abdelwahab N, Abdelrahim M, Diab A, Yee C, Abudayyeh A. Infliximab for the treatment of patients with checkpoint inhibitor-associated acute tubular interstitial nephritis. Oncoimmunology. 2021 Feb 2;10(1):1877415. doi: 10.1080/2162402X.2021.1877415. PMID: 33643693; PMCID: PMC7872057.

2: Lin JS, Wang DY, Mamlouk O, Glass WF, Abdelrahim M, Yee C, Abudayyeh A. Immune checkpoint inhibitor associated reactivation of primary membranous nephropathy responsive to rituximab. J Immunother Cancer. 2020 Oct;8(2):e001287. doi: 10.1136/jitc-2020-001287. PMID: 33020246; PMCID: PMC7537330.

3: Mamlouk O, Lin JS, Abdelrahim M, Tchakarov AS, Glass WF, Selamet U, Buni M, Abdel-Wahab N, Abudayyeh A. Checkpoint inhibitor-related renal vasculitis and use of rituximab. J Immunother Cancer. 2020 Jul;8(2):e000750. doi: 10.1136/jitc-2020-000750. PMID: 32718987; PMCID: PMC7380836.

4: Pankow JD, Richard-Carpentier G, Daver NG, Glass WF 2nd, Kala J. Unique case of ANCA-negative pauci-immune necrotizing glomerulonephritis with diffuse alveolar hemorrhage, potentially associated with midostaurin. CEN Case Rep. 2020 May;9(2):147-151. doi: 10.1007/s13730-020-00443-3. Epub 2020 Jan 18. PMID: 31955389; PMCID: PMC7148408.

5: El Achi H, Glass WF, Wang W, Medeiros LJ, Hu Z. Reactive lymphadenopathy with concurrent idiopathic plasma cell variant Castleman disease, amyloid deposition and non-caseating granulomas. Pathology. 2019 Dec;51(7):762-764. doi: 10.1016/j.pathol.2019.09.003. Epub 2019 Oct 26. PMID: 31662201.

6: Aria AB, Chen L, Glass WF, Lahoti A, Chon SY. Leukocytoclastic vasculitis with late-onset Henoch-Schönlein purpura after trifluridine/tipiracil treatment. Dermatol Online J. 2018 Oct 15;24(10):13030/qt75g3b1kv. PMID: 30677817.

7: Mamlouk O, Selamet U, Machado S, Abdelrahim M, Glass WF, Tchakarov A, Gaber L, Lahoti A, Workeneh B, Chen S, Lin J, Abdel-Wahab N, Tayar J, Lu H, Suarez- Almazor M, Tannir N, Yee C, Diab A, Abudayyeh A. Nephrotoxicity of immune checkpoint inhibitors beyond tubulointerstitial nephritis: single-center experience. J Immunother Cancer. 2019 Jan 6;7(1):2. doi: 10.1186/s40425-018-0478-8. PMID: 30612580; PMCID: PMC6322290.

8: Strati P, Glass WF, Abdelrahim M, Selamet U, Tchakarov A, Workeneh BT, Verstovsek S, Abudayyeh A. Renal complications of primary myelofibrosis. Leuk Lymphoma. 2019 Feb;60(2):507-510. doi: 10.1080/10428194.2018.1474525. Epub 2018 Jul 3. PMID: 29966471.

9: Chu JR, Dierksen JE, Glass WF, Aisenberg GM. Association of membranoproliferative glomerulonephritis with mantle cell lymphoma. BMJ Case Rep. 2013 Oct 7;2013:bcr2013009730. doi: 10.1136/bcr-2013-009730. PMID: 24099759; PMCID: PMC3822269.

10: Hedelius R, Fletcher JJ, Glass WF 2nd, Susanti AI, Maguire JD. Nephrotic syndrome and unrecognized Plasmodium malariae infection in a US Navy sailor 14 years after departing Nigeria. J Travel Med. 2011 Jul-Aug;18(4):288-91. doi: 10.1111/j.1708-8305.2011.00526.x. Epub 2011 Jun 15. PMID: 21722243.

11: Yang C, Glass WF 2nd. Expression of alpha-actinin-1 in human glomerular mesangial cells in vivo and in vitro. Exp Biol Med (Maywood). 2008 Jun;233(6):689-93. doi: 10.3181/0710-RM-279. Epub 2008 Apr 11. PMID: 18408146.

12: Yang C, Patel K, Harding P, Sorokin A, Glass WF 2nd. Regulation of TGF- beta1/MAPK-mediated PAI-1 gene expression by the actin cytoskeleton in human mesangial cells. Exp Cell Res. 2007 Apr 1;313(6):1240-50. doi: 10.1016/j.yexcr.2007.01.011. Epub 2007 Jan 31. PMID: 17328891; PMCID: PMC1896147.

13: Harding P, Balasubramanian L, Swegan J, Stevens A, Glass WF 2nd. Transforming growth factor beta regulates cyclooxygenase-2 in glomerular mesangial cells. Kidney Int. 2006 May;69(9):1578-85. doi: 10.1038/sj.ki.5000323. PMID: 16572115.

14: Ciavarra RP, Holterman DA, Brown RR, Mangiotti P, Yousefieh N, Wright GL Jr, Schellhammer PF, Glass WF, Somers KD. Prostate tumor microenvironment alters immune cells and prevents long-term survival in an orthotopic mouse model following flt3-ligand/CD40-ligand immunotherapy. J Immunother. 2004 Jan- Feb;27(1):13-26. doi: 10.1097/00002371-200401000-00002. PMID: 14676630.

15: Ciavarra RP, Brown RR, Holterman DA, Garrett M, Glass WF 2nd, Wright GL Jr, Schellhammer PF, Somers KD. Impact of the tumor microenvironment on host infiltrating cells and the efficacy of flt3-ligand combination immunotherapy evaluated in a treatment model of mouse prostate cancer. Cancer Immunol Immunother. 2003 Sep;52(9):535-45. doi: 10.1007/s00262-003-0383-x. PMID: 14627125.

16: Somers KD, Brown RR, Holterman DA, Yousefieh N, Glass WF, Wright GL Jr, Schellhammer PF, Qian J, Ciavarra RP. Orthotopic treatment model of prostate cancer and metastasis in the immunocompetent mouse: efficacy of flt3 ligand immunotherapy. Int J Cancer. 2003 Dec 10;107(5):773-80. doi: 10.1002/ijc.11464. PMID: 14566827.

17: Wu J, Borillo J, Glass WF, Hicks J, Ou CN, Lou YH. T-cell epitope of alpha3 chain of type IV collagen induces severe glomerulonephritis. Kidney Int. 2003 Oct;64(4):1292-301. doi: 10.1046/j.1523-1755.2003.00227.x. PMID: 12969147.

18: Patel K, Harding P, Haney LB, Glass WF 2nd. Regulation of the mesangial cell myofibroblast phenotype by actin polymerization. J Cell Physiol. 2003 Jun;195(3):435-45. doi: 10.1002/jcp.10267. PMID: 12704653.

19: Harding P, Glass WF 2nd, Scherer SD. COX-2 inhibition potentiates the antiproteinuric effect of enalapril in uninephrectomized SHR. Prostaglandins Leukot Essent Fatty Acids. 2003 Jan;68(1):17-25. doi: 10.1016/s0952-3278(02)00231-4. PMID: 12538086.

20: Wu J, Hicks J, Borillo J, Glass WF 2nd, Lou YH. CD4(+) T cells specific to a glomerular basement membrane antigen mediate glomerulonephritis. J Clin Invest. 2002 Feb;109(4):517-24. doi: 10.1172/JCI13876. PMID: 11854324; PMCID: PMC150874.